Follistatin-344 vs 315: The Splice Variants Explained

What is follistatin, and why are there different numbers attached to it?

Follistatin is a secreted protein encoded by the FST gene. Its main job, extensively documented in the preclinical literature, is binding and neutralizing activin and myostatin, two members of the TGF-beta superfamily that restrain muscle growth and regulate other tissues (Lee & Lee, 2004; Rodino-Klapac et al., 2006). That myostatin-blocking mechanism is the whole reason follistatin shows up in muscle-wasting research and, separately, in unregulated products marketed to bodybuilders.

The gene itself does not produce one single protein. Through alternative splicing of its final exon, FST generates isoforms that differ at the C-terminal end. The literature commonly refers to these as FST315 and FST288, with FST303 arising as a proteolytic cleavage product of FST315. These are not interchangeable versions of the same drug. They differ in where they go and what they bind once secreted.

A commercial product labeled "Follistatin-344" is naming the precursor, the full-length translated protein before the signal peptide is clipped off during normal cellular processing. That precursor length is not the same as the mature, secreted, biologically active form. This is the source of a lot of confusion in forums and vendor marketing, and it is worth being precise about because it affects what a buyer is actually purchasing.

Which form actually circulates in the human body?

FST315 is generally described as the predominant circulating serum isoform. It has weaker affinity for cell-surface heparan sulfate proteoglycans, which lets it travel more freely in blood and act at a distance from where it was made, more like a classic endocrine signal.

FST288, by contrast, binds cell-surface proteoglycans tightly and tends to act locally, near its site of production, rather than circulating systemically. Its biological role has been studied specifically in reproductive tissue: mice lacking follistatin 288 show altered activin expression and morphological abnormalities in the male reproductive tract, indicating this isoform has tissue-specific jobs distinct from a generic muscle-growth signal (Oduwole et al., 2017). Separate work indicates the follistatin N-terminal region differentially affects muscle size versus fat depending on which construct is used, meaning the biological effect is not identical across follistatin variants even in animal models (Braga et al., 2017).

Exact amino acid counts vary slightly across species and papers, so treat specific numbers as approximate landmarks rather than fixed universal constants. The consistent finding across sources is structural: there are at least two functionally distinct follistatin forms with different circulation behavior, and the marketed "344" label does not map cleanly onto either of them.

Does the biology support what's being sold as "Follistatin-344"?

This is the practical question, and the honest answer is: not clearly.

The preclinical evidence for follistatin as a myostatin inhibitor is real and comes mostly from gene therapy delivery, not injected recombinant protein. Studies in dystrophic mice used AAV-delivered follistatin to increase local muscle expression over time (Kota et al., 2008; Rodino-Klapac, 2013), and the only controlled human data come from a phase 1/2a gene therapy trial in Becker muscular dystrophy, which reported functional improvements in ambulation over roughly a year of follow-up (Mendell et al., 2015; Al-Zaidy et al., 2015). A related trial in sporadic inclusion body myositis reported similar functional signals (Mendell et al., 2017).

None of that translates directly to a vial of injectable "Follistatin-344" peptide bought online. Gene therapy changes what cells produce, continuously, at a controlled dose, under trial-grade quality control. An injected recombinant protein, sold outside any pharmacy compounding framework, is a completely different delivery mechanism with no equivalent human safety or efficacy data. Follistatin-344 is not on the FDA's 503A bulk drug substances list used for compounding oversight (FDA 503A bulk substances), and it has no FDA-approved indication of any kind.

There is also a basic identity problem. A buyer cannot verify from a vial label whether the product is folded correctly, whether it matches the precursor or mature sequence, or whether it retains any activin/myostatin-binding activity at all. Even taking the underlying biology at face value, the commercial supply chain has not demonstrated it delivers that biology.

A framework for evaluating what you're actually being offered

If you are trying to decide whether a product's biology "makes sense," walk through each row. A vendor claiming their product mimics natural muscle-building follistatin activity needs to explain which native isoform it resembles, what evidence supports that resemblance, and how a buyer would ever confirm it. Most vendor materials answer none of these.

What is established, what is plausible, and what is not established

Established: follistatin's role as an activin/myostatin antagonist is well supported preclinically, and native follistatin exists as multiple splice variants with distinct circulation patterns and tissue roles (Lee & Lee, 2004; Oduwole 2017).

Plausible but unproven: that a recombinant peptide labeled to match one of these forms would behave identically once manufactured outside controlled gene-therapy delivery, and that it would reach muscle tissue at a biologically meaningful concentration when self-injected.

Not established: that any commercially sold "Follistatin-344" product replicates the sequence, folding, or activity of a native human isoform, that it produces the muscle effects seen in mouse or gene therapy studies, or that it is safe for unsupervised human use. See the FDA Peptide Status Tracker for current regulatory status across the peptide category, and check current data before assuming anything here still holds, since compounding and enforcement status can change.

Where to go next

For the mechanism itself, see how follistatin inhibits myostatin. For a deeper look at what the animal and human gene therapy data actually show, see the muscle evidence review and the gene therapy trials specifically. If you're weighing this against options with actual human safety data, follistatin vs creatine covers a mainstream comparison point.